Product Name: IL-1RA Antibody (biotin)
Species Reactivity: Human
Tested Applications: ELISA, WB
Applications: ELISA:Direct:To detect Human IL-1RA by direct ELISA (using 100 μL/well antibody solution) a concentration of 0.25 – 1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2 – 0.4 ng/well of recombinant Human IL-1RA.SandwichTo detect Human IL-1RA by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.25 – 1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with our polyclonal Anti-Human IL-1RA as a capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant Human IL-1RA. Western Blot:To detect Human IL-1RA by Western Blot analysis this antibody can be used at a concentration of 0.1 – 0.2 μg/mL. When used in conjunction with compatible secondary reagents the detection limit for recombinant Human IL-1RA is 1.5 – 3.0 ng/lane, under either reducing or non-reducing conditions.
User Note: Centrifuge vial prior to opening.
Predicted Molecular Weight:
Immunogen: Produced from sera of rabbits immunized with highly pure recombinant Human IL-1RA. Human IL-1RA specific antibody was purified by affinity chromatography and then biotinylated.
Host Species: Rabbit
Purification:
Physical State: Lyophilized
CAS NO.: 38363-32-5
Product: Acalabrutinib
Buffer:
Concentration:
Storage Conditions: IL-1RA antibody is stable for at least 2 years from date of receipt at -20˚C. The reconstituted antibody is stable for at least two weeks at 2-8˚C. Frozen aliquots are stable for at least 6 months when stored at -20˚C. Avoid repeated freeze-thaw cycles.
Clonality: Polyclonal
Conjugate: Biotin
Alternate Names: DIRA, IRAP, IL1F3, IL1RA, MVCD4, IL-1RN, IL-1ra, IL-1ra3, ICIL-1RA, Interleukin-1 receptor antagonist protein
Accession NO.: P18510
Protein Ino: 124312
Official Symbol: IL1RN
Geneid: 3557
Background:
PubMed ID:http://aac.asm.org/content/26/2/277.abstract
